In today’s session Sarepta Therapeutics Inc (SRPT) registered an unusually high (6,584) contracts volume of call trades. Someone, most probably a professional was a very active buyer of the January, 2017 call, expecting serious SRPT increase. With 6,584 contracts traded and 44724 open interest for the Jan, 17 contract, it seems this is a quite bullish bet. The option with symbol: SRPT170120C00045000 closed last at: $4.4 or 29% down. About 699,853 shares traded hands. Sarepta Therapeutics Inc (NASDAQ:SRPT) has risen 114.25% since March 29, 2016 and is uptrending. It has outperformed by 110.77% the S&P500.
Analysts await Sarepta Therapeutics Inc (NASDAQ:SRPT) to report earnings on November, 3. They expect $-1.31 earnings per share, down 4.80% or $0.06 from last year’s $-1.25 per share. After $-1.34 actual earnings per share reported by Sarepta Therapeutics Inc for the previous quarter, Wall Street now forecasts -2.24% EPS growth.
Sarepta Therapeutics Inc (NASDAQ:SRPT) Ratings Coverage
Out of 21 analysts covering Sarepta Therapeutics (NASDAQ:SRPT), 12 rate it a “Buy”, 1 “Sell”, while 8 “Hold”. This means 57% are positive. $108 is the highest target while $4 is the lowest. The $53.82 average target is 33.09% above today’s ($40.44) stock price. Sarepta Therapeutics has been the topic of 52 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The company was maintained on Thursday, August 20 by Roth Capital. The company was maintained on Wednesday, August 5 by Roth Capital. The stock has “Neutral” rating given by Piper Jaffray on Monday, January 18. As per Tuesday, August 25, the company rating was upgraded by Vetr. The rating was initiated by Morgan Stanley with “Equal-Weight” on Thursday, October 27. The rating was downgraded by Oppenheimer to “Perform” on Tuesday, April 26. The stock of Sarepta Therapeutics Inc (NASDAQ:SRPT) has “Outperform” rating given on Tuesday, October 18 by Credit Suisse. The rating was upgraded by Piper Jaffray to “Overweight” on Monday, August 24. As per Friday, October 2, the company rating was maintained by Needham. Janney Capital initiated the stock with “Neutral” rating in Wednesday, April 20 report.
According to Zacks Investment Research, “Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics for the treatment of rare and infectious diseases. The Company’s diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy. Sarepta Therapeutics, Inc., formerly known as AVI BioPharma, Inc., is headquartered in Bothell, Washington.”
Insitutional Activity: The institutional sentiment increased to 1.16 in Q2 2016. Its up 0.32, from 0.84 in 2016Q1. The ratio improved, as 31 funds sold all Sarepta Therapeutics Inc shares owned while 32 reduced positions. 31 funds bought stakes while 42 increased positions. They now own 33.70 million shares or 3.23% less from 34.83 million shares in 2016Q1.
First Midwest Natl Bank Tru Division holds 32,954 shares or 0.08% of its portfolio. Bank & Trust Of Montreal Can accumulated 261,301 shares or 0.01% of the stock. Moreover, Cubist Systematic Strategies Limited Com has 0% invested in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 274 shares. The Virginia-based Quantitative Mngmt Limited Com has invested 0.15% in Sarepta Therapeutics Inc (NASDAQ:SRPT). Millennium Ltd Liability last reported 0.01% of its portfolio in the stock. Guardian holds 166 shares or 0% of its portfolio. North Star Mgmt Corporation accumulated 735 shares or 0% of the stock. Apriem Advsr reported 5,800 shares or 0.04% of all its holdings. Fmr Ltd has 1.80 million shares for 0% of their US portfolio. Quantitative Systematic Strategies Limited Co last reported 11,293 shares in the company. Acuta Cap Prns Ltd Liability Co reported 130,000 shares or 1.19% of all its holdings. Carl Domino last reported 13,000 shares in the company. Ameriprise holds 0% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT) for 56,887 shares. Employees Retirement Association Of Colorado accumulated 0% or 12,338 shares. Art Limited has invested 0.2% of its portfolio in Sarepta Therapeutics Inc (NASDAQ:SRPT).
Insider Transactions: Since September 14, 2016, the stock had 0 insider buys, and 8 selling transactions for $8.94 million net activity. 9,304 shares with value of $465,200 were sold by Howton David T on Monday, September 19. 24,557 Sarepta Therapeutics Inc (NASDAQ:SRPT) shares with value of $736,710 were sold by Kaye Edward M. MD. On Thursday, September 22 the insider Ruff Shamim sold $438,660. 30,000 Sarepta Therapeutics Inc (NASDAQ:SRPT) shares with value of $1.50M were sold by Mahatme Sandesh. Aphale Jayant had sold 35,000 shares worth $1.75M on Monday, September 19.
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $2.14 billion. The Firm is focused on the discovery and development of ribonucleic acid -targeted therapeutics for the treatment of rare, infectious and other diseases. It currently has negative earnings. The Firm operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
SRPT Company Profile
Sarepta Therapeutics, Inc., incorporated on June 5, 2013, is a biopharmaceutical company. The Firm is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Firm is engaged in the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Firm is primarily focused on advancing the development of its disease-modifying Duchenne Muscular Dystrophy (DMD) drug candidates, including its lead DMD product candidate, eteplirsen, designed to skip exon 51. The Firm is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases.
More notable recent Sarepta Therapeutics Inc (NASDAQ:SRPT) news were published by: Profitconfidential.com which released: “Sarepta Therapeutics Inc: $40.00 is Price Support on SRPT stock” on October 30, 2016, also Finance.Yahoo.com with their article: “Sarepta Therapeutics (SRPT) Incurs Narrower Y/Y Loss in Q3” published on October 28, 2016, Fool.com published: “Better Buy: Alnylam Pharmaceuticals, Inc. vs. Sarepta Therapeutics, Inc.” on October 10, 2016. More interesting news about Sarepta Therapeutics Inc (NASDAQ:SRPT) were released by: Finance.Yahoo.com and their article: “Sarepta Therapeutics reports 3Q loss” published on October 27, 2016 as well as Nasdaq.com‘s news article titled: “Earnings Reaction History: Sarepta Therapeutics, Inc., 71.4% Follow-Through …” with publication date: October 27, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.